Table 3

Clinical cure rate at the isolate level: selected baseline isolates at test-of-cure visit (ME population)*
Isolate Tigecycline Comparator
n/N % n/N %
Staphylococcus aureus 54/71 76.1 49/61 80.3
 MRSA 25/36 69.4 21/29 72.4
 CA-MRSA 17/25 68.0 17/23 73.9
 MSSA 29/35 82.9 28/32 87.5
Streptococcus spp. 30/36 83.3 15/25 60.0
S. pyogenes 8/11 72.7 5/5 100
S. agalactiae 9/9 100 3/6 50.0
S. anginosus groupa 8/9 88.9 3/8 37.5
Enterobacter cloacae 5/8 62.5 1/1 100
Enterococcus spp.b 5/7 71.4 6/6 100
Escherichia coli 10/13 76.9 7/8 87.5
Klebsiella pneumoniae 5/5 100 5/6 83.2
Proteus spp.c 4/7 57.1 2/2 100
Pseudomonas aeruginosa 5/7 71.4 2/2 100

*No statistically significant differences between groups. ME, microbiologically evaluable; MRSA, methicillin-resistant Staphylococcus aureus; CA-MRSA, community-acquired MRSA; MSSA, methicillin-susceptible Staphylococcus aureus. aStreptococcus anginosis, Streptococcus intermedius, Streptococcus constellatus;bEnterococcus faecalis, Enterococcus faecium;cProteus mirabilis, Proteus penneri, Proteus vulgaris group.

Matthews et al.

Matthews et al. BMC Infectious Diseases 2012 12:297   doi:10.1186/1471-2334-12-297

Open Data